Clinical and experimental reproductive medicineAug 3, 2026

Nicotinamide mononucleotide's potential to support ovarian health based on preclinical studies

Longevity & Aging Weekly Brief ↗PubMed ↗DOI ↗

Updated Aug 4, 2026

Abstract

Nicotinamide mononucleotide (NMN) supplementation may improve ovarian health by enhancing mitochondrial function and reducing oxidative stress.

Animal studies indicate that NMN may enhance mitochondrial function in ovarian tissue.
NMN administration is associated with improved oocyte quality and delayed ovarian aging.
In models of chemotherapy-induced ovarian insufficiency, NMN may increase folliculogenesis and normalize hormonal profiles.
The anti-inflammatory and anti-apoptotic effects of NMN suggest potential benefits for conditions like premature ovarian insufficiency and polycystic ovary syndrome.
Despite promising preclinical findings, the clinical application of NMN in humans requires further investigation.

Simplified

Nicotinamide mononucleotide (NMN), a key precursor of nicotinamide adenine dinucleotide (NAD+), has recently emerged as a promising therapeutic candidate for age-related diseases. This review critically evaluates preclinical evidence regarding the effects of NMN on ovarian health, with particular emphasis on its potential to attenuate ovarian aging, improve follicular reserve, and restore endocrine function. Animal studies have demonstrated that NMN supplementation enhances mitochondrial function, reduces oxidative stress, and modulates sirtuin activity in ovarian tissue. These effects contributed to improved oocyte quality, delayed ovarian senescence, and prolonged reproductive lifespan. In models of chemotherapy-induced ovarian insufficiency and age-related ovarian decline, NMN administration was associated with increased folliculogenesis and normalization of hormonal profiles. Furthermore, the anti-inflammatory and anti-apoptotic properties of NMN suggest potential therapeutic applications in conditions such as premature ovarian insufficiency and polycystic ovary syndrome. Despite encouraging findings in rodent models, clinical translation remains limited. This review summarizes the key molecular pathways influenced by NMN, including the NAD+/sirtuin-1 (SIRT1) axis, and highlights important gaps in current knowledge. Collectively, the available evidence underscores the therapeutic potential of NMN while emphasizing the need for well-designed human studies to establish its efficacy and safety in reproductive medicine.

Full Text

Full text is available at the source.

View Full Text ↗

Nicotinamide mononucleotide's potential to support ovarian health based on preclinical studies

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the longevity & aging brief